Pfizer Ltd reported an 85 per cent year-on-year (YoY) increase in net profit for the fourth quarter of FY25, reaching ₹330.94 crore, driven by an exceptional gain from the completion of an asset sale and transfer. In comparison, the company had recorded a net profit of ₹178.86 crore in the fourth quarter of FY24, according to its regulatory filing.
Total expenses in Q4FY25 rose marginally to ₹383.5 crore, up from ₹377.9 crore in the corresponding quarter of the previous year.
The company’s board of directors has recommended a total dividend of ₹165 per equity share of ₹10 each for FY25. This. A final dividend of ₹35 per share
A special dividend of ₹100 per share to commemorate Pfizer’s 75th year in India
An additional special dividend of ₹30 per share linked to the gain from the transfer of leasehold land and buildings
Revenue from operations for Q4FY25 rose by 8.3 per cent year-on-year to ₹591.91 crore, compared to ₹546.63 crore in Q4FY24.
During the quarter, Pfizer recorded an exceptional gain of ₹172.81 crore from the completion of the transfer and sale of land, including structures and buildings, at Thane to Zoetis Pharmaceutical Research Pvt Ltd, as per the regulatory filing.
